General MedicationsORALGeneric
OXBRYTA
VOXELOTOR
Standard Dose
300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview OXBRYTA is listed in Drugs@FDA under application 213137 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient VOXELOTOR Form and strength TABLET;ORAL - 300MG Sponsor GLOBAL BLOOD THERAPS Submission history Latest submission status date: 2023-08-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview OXBRYTA is listed in Drugs@FDA under application 213137 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient VOXELOTOR Form and strength TABLET;ORAL - 300MG Sponsor GLOBAL BLOOD THERAPS Submission history Latest submission status date: 2023-08-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.